Description
DORZOLAMID-OPTIC Pharmacodynamics
DORZOLAMID-OPTIK contains the carboanhydrase II inhibitor dorzolamide hydrochloride. Inhibition of carboanhydrase (CA) in the ciliary body of the eyeball reduces the production of intraocular fluid, presumably by inhibiting the synthesis of bicarbonate ions with their subsequent reduction to sodium and fluid excretion. This results in a decrease in intraocular pressure (IOP).
Indications
DORZOLAMID-OPTIK is prescribed to adult patients with:
– ophthalmohypertension;
– Primary open-angle glaucoma;
– Pseudoexfoliative glaucoma;
– secondary glaucoma (without anterior chamber angle block).
DORZOLAMID-OPTIK is prescribed for children:
– for the treatment of glaucoma in children from week 1 in monotherapy or as an adjunct to treatment with beta-adrenoblockers.
Contraindications
– Hypersensitivity to dorzolamide and/or any excipients in the drug;
– Age less than 1 week;
– Chronic renal insufficiency;
– Pregnancy;
– Breast-feeding period.
Dosage and administration method
- Topically.
- When using DORZOLAMID-OPTIC the normal dosage is 1 drop in the affected eye (or both eyes) 3 times a day (morning, afternoon and evening).
- If any anti-glaucoma drug is replaced by DORZOLAMID-OPTIC, treatment with DORZOLAMID-OPTIC should be started the day after the previous drug is withdrawn.
- If DORZOLAMID-OPTIC is used simultaneously with other eye drops, they should be injected at least 10 minutes apart.
